Cagrilintide — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Long-acting amylin analogue (AMY1 class)
Reported half-life: Approximately 7–8 days
Routes used in the literature: Subcutaneous
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Phase 2 monotherapy escalation

Reported quantity: 0.3 mg escalating through 0.6, 1.2, 2.4 to 4.5 mg weekly
Frequency: Once weekly
Study duration: 26 weeks

Effect increased across the escalation range in the published dose-finding work.

Combination arms with a GLP1-class agonist

Reported quantity: 2.4 mg cagrilintide alongside 2.4 mg of the GLP1-class agent (semaglutide)
Frequency: Once weekly
Study duration: 20–68 weeks

Combination arms are the main focus of the current literature.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

Cagrilintide · 10 mg Vial

Cagrilintide is dosed at 600 mcg–4.5 mg weekly by subcutaneous injection in educational protocols, starting low and titrating upward. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 0.0333 mg (33.3 mcg) on a U‑100 insulin syringe.
Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.

Week/Phase	Weekly Dose (mg)	Units (per injection)	Volume (mL)
Weeks 1–2	0.6 mg	18 units	0.18 mL
Weeks 3–4	1.2 mg	36 units	0.36 mL
Weeks 5–6	2.4 mg	72 units	0.72 mL
Weeks 7–16 (Maintenance)	4.5 mg	135 units	1.35 mL

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size Cagrilintide is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

Cagrilintide · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	600 mcg =	4.50 mg =
5 mg	1.67 mg/ml	17 mcg	36 units	270 units
10 mg	3.33 mg/ml	33 mcg	18 units	135 units

Unit columns use the range reported for this compound (600 mcg–4.50 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 5 mg vial in 2 mL of bacteriostatic water gives 2.5 mg/mL.

Open the reconstitution calculator

How to read these figures

Amylin pharmacology overlaps with but is distinct from incretin pharmacology.
Nausea is the dose-limiting finding reported across the escalation arms.
Combination figures should never be read as additive single-compound figures.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, et al. · Lancet · 2021 · PMID 34798060
Adults with overweight/obesity received once-weekly subcutaneous cagrilintide at doses of 0.3-4.5 mg for 26 weeks in a dose-finding phase 2 trial.
View the record
[2]
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frías JP, Deenadayalan S, Erichsen L, et al. · Lancet · 2023 · PMID 37364590
Patients with type 2 diabetes received once-weekly subcutaneous co-administration of cagrilintide 2.4 mg with semaglutide 2.4 mg over a 32-week treatment period.
View the record
[3]
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
(CagriSema Trial Investigators) · N Engl J Med · 2025 · DOI 10.1056/NEJMoa2502081
Phase 3 trial in which adults with overweight/obesity received once-weekly subcutaneous cagrilintide 2.4 mg co-administered with semaglutide 2.4 mg (CagriSema) over an extended treatment period.
View the record

Search the databases yourself

Read the Cagrilintide research brief

Other metabolic compounds

AdipotidePro-apoptotic peptidomimetic targeting prohibitin in white adipose vasculature AICARAMP analogue and AMPK activator (small molecule, not a peptide)GLP1 (semaglutide / Ozempic)GLP-1 receptor agonist GLP2 (tirzepatide / Mounjaro)Dual GIP/GLP-1 receptor agonist

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.